Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.

Eli Lilly & Co. tumbled as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...